| Full package$ | Stand-alone | RR (95% CI) # |
---|---|---|---|
Sites, N (%) | 18 (56%) | 14 (44%) | - |
Total HIV positive pregnant women (N) | 743 | 195 | - |
CD4 cell count assessment, N (%): | Â | Â | Â |
   Screened for CD4 cell counts¶ | 547 (74%) | 111 (57%) | 1.3 (1.1 - 1.4) |
   Received CD4 cell count result¶¶ | 536 (98%) | 111 (100%) | 0.97 (0.96 - 1.0) |
   CD4 cell count < 350 cells/mm3 | 134 (25%) | 26 (23%) | - |
Enrolment into care and treatment, N (%) | 495 (67%) | 69 (35%) | 1.9 (1.5 - 2.3) |
HAART initiation among women with CD4 cell counts < 350 cells/mm3, N (%) | 105 (78%) | 22 (85%) | 0.9 (0.7 - 1.1) |
Received PMTCT prophylaxis or more efficacious ARV regimens: | 511 (96%) | 106 (100%) | 0.9 (0.9 - 1.0) |
   Dual (AZT/sd-nvp) prophylaxis | 331 (62%) | 72 (68%) | - |
   HAART for life | 105 (20%) | 22 (21%) | - |
   Short-course HAART | 75 (14%) | 12 (11%) | - |
sd-nvp only | 21 (4%) | 0 (0%) | - |